Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Brain : a journal of neurology·2026
Same author

Neuropathic pain in multiple sclerosis: discrepancies between DN4 screening and neurophysiological measures.

Multiple sclerosis and related disorders·2026
Same author

Associations of chrononutrition and sleep with fatigue in multiple sclerosis: an analysis of the Swiss Multiple Sclerosis Registry.

BMJ neurology open·2026
Same author

Sex differences in the development, treatment, and prognosis of multiple sclerosis in Switzerland.

Frontiers in neuroscience·2026
Same author

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: a retrospective international cohort study.

The Lancet. Neurology·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K

[Treatments for multiple sclerosis: update].

Marjolaine Uginet1, Lucie Lefeuvre1, Julien Lerusse1

  • 1Unité de neuro-immunologie, Service de neurologie, Département des neurosciences cliniques, Hôpitaux universitaires de Genève et Faculté de médecine, 1211 Genève 4.

Revue Medicale Suisse
|April 26, 2024
PubMed
Summary
This summary is machine-generated.

Recent advances in multiple sclerosis (MS) management include highly effective treatments, particularly anti-CD20 antibodies, now available for progressive forms. Understanding their mechanisms and risks, like opportunistic infections, is crucial for effective MS care.

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.3K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.7K

Related Experiment Videos

Last Updated: Jun 27, 2025

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.3K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.7K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) management has been transformed by novel, highly effective therapies.
  • Therapeutic interventions are increasingly initiated early, sometimes before clinical diagnosis.

Purpose of the Study:

  • To review the current landscape of progression-preventing treatments for MS available in 2024.
  • To highlight the role and considerations of anti-CD20 antibodies in MS therapy, including progressive forms.

Main Methods:

  • Literature review of recent therapeutic advancements in multiple sclerosis.
  • Analysis of treatment mechanisms, efficacy, and safety profiles.

Main Results:

  • The therapeutic arsenal for MS now includes potent disease-modifying therapies.
  • Anti-CD20 antibodies are a cornerstone treatment, with expanding indications for progressive MS.
  • Immunosuppressive therapies necessitate careful monitoring for potential risks, such as opportunistic infections.

Conclusions:

  • The management of MS has significantly evolved, offering improved control over disease progression.
  • Anti-CD20 therapies represent a major therapeutic advance, requiring a thorough understanding of their benefits and risks.
  • Informed clinical decision-making is essential for optimizing patient outcomes in MS management.